<DOC>
	<DOCNO>NCT01521975</DOCNO>
	<brief_summary>Based GLOBE study supply predictability analysis result , ROADMAP strategy provide individualized telbivudine treatment roadmap strategy design achieve optimal viral suppression low resistance rate patient chronic hepatitis B ( CHB ) , include add ADV treatment different time point accord individual patient response . China CHB Guidelines ( China Medical Association 2010 ) make impress confirm LDT ROADMAP strategy particularly , may large potential expand naïve patient . We lack optimal model HBeAg ( - ) . In China HBeAg ( - ) around 38 % total CHB patient . In GLOBE study , LdT treatment HBeAg ( - ) patient HBV DNA &lt; 7log show good 2 year efficacy , still look forward efficient treatment low resistance rate . This study comply principle individualized therapy recommend ethical principle . It expect study design individualize treatment approach may improve efficacy low resistance rate . In addition , provide important information bring great benefit patient CHB .</brief_summary>
	<brief_title>A Two-year Study Telbivudine HBeAg Negative Hepatitis</brief_title>
	<detailed_description>This study open-label , multicenter , PCR response adaptive clinical study design , intensification treatment ( addition adefovir telbivudine treatment ) depend HBV DNA level week 24 . All patient commence Telbivudine 600mg daily . At week 24 divide 2 Groups accord virological response . Patients PCR detectable HBV DNA add ADV ( Group I ) . Patients PCR undetectable HBV DNA ( Group II ) continue telbivudine monotherapy . ADV add unless viral breakthrough occurs .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Detectable serum HBsAg Screening visit least 6 month prior HBeAg negative Screening visit serum HBV DNA level &gt; 2,000 IU/mL Screening visit Elevated serum ALT≥2 ×ULN &lt; 10×ULN Screening visit ( exclude ALT elevation due nonHBV reason drug , alcohol etc ) Patient history clinical signs/symptoms hepatic decompensation ( ChildPugh Grade B C ) ascites , esophageal variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis . Patient history hepatocellular carcinoma ( HCC ) suspect symptoms HCC , suspicious focus image study and/or serum alphafetoprotein ( AFP ) &gt; 50ng/mL . Patient receive treatment nucleoside nucleotide drug whether approve investigational . Patient receive IFN immunomodulatory treatment within 52 week Screening . Patient medical condition require frequent use systemic acyclovir famciclovir . Patient medical condition require frequent use systemic corticosteroid , however topical inhaled corticosteroid allow . Patient use hepatotoxic drug within one month . Patient overtaken alcohol ( &gt; 40g/day ) abuse illicit drug recent one year . Use investigational drug time enrollment . History hypersensitivity study drug ( telbivudine adefovir ) . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive urine pregnancy test . Patient coinfected HCV , HDV HIV . Patient one additional know primary secondary cause liver disease , hepatitis B ( e.g. , alcoholism , autoimmune hepatitis ) . History malignancy organ system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>HBV DNA</keyword>
	<keyword>LdT</keyword>
	<keyword>ADV</keyword>
	<keyword>HBeAg negative hepatitis</keyword>
	<keyword>CHB</keyword>
</DOC>